AWS and Novo Nordisk: AI transforms drug discovery beyond data centers

Bullish Gator

AWS CEO Matt Garman outlines an AI-driven partnership with Novo Nordisk to accelerate drug discovery using cloud and advanced AI tools.

Editorial companion

What stands out

Matt Garman, CEO of Amazon Web Services (AWS), told Fox Business that AWS is taking its artificial intelligence (AI) toolset out of the data center and into drug discovery through a partnership with Novo Nordisk. That matters because it marks a practical pivot, cloud providers selling domain-specific science services rather than just raw compute. For investors watching AMZN, it turns AI from an infrastructure story into a potential revenue pipeline tied to long, high-value pharma deals, real dollars but long lead times and regulatory risk.